Event-dense runway: management frames the coming quarters as a calendar of its own named, scheduled events
The model's full reasoning — Q4 2016 call → NOWe need to determine if management frames the near future as a calendar of its own specific, named, already-scheduled events, and treats working through that event sequence as the central story. The transcript includes forward-looking statements. Let's examine what management says about the near future. Irene mentions: "We're seeing early success from our launches of Milka chocolate in China, and the repatriation of our Nabisco biscuit trademarks in Japan, and we just entered the U.S. chocolate market with Milka Oreo and GREEN & BLACK'S." These are recent launches, but are they upcoming events? They are already done. She also mentions "we just entered" - so that's past. Brian mentions: "We expect headwinds in the first quarter and potentially into Q2" regarding India demonetization. That's a macro impact, not a company event. They talk about 2017 outlook: "we expect full-year organic net revenue to grow at least 1%." That's a target, not an event. They mention "new white space launches" as part of the outlook, but not specific named events with timing. They mention "the timing of Easter, the Chinese New Year" as factors affecting first quarter growth. Those are seasonal events, not company-specific scheduled actions. They mention "we're building an industry-leading eCommerce snacks business, targeting at least $1 billion in revenue by 2020." That's a long-term target. They mention "we just entered the U.S. chocolate market" - that's past. They mention "we're seeing early success from our launches" - past. They mention "we're well on track to deliver our adjusted OI margin target of 17% to 18% by 2018." That's a target. They mention "we have good visibility to expand margins beyond that." Not an event. They mention "we announced an agreement to sell most of our grocery business in Australia and New Zealand" - that's a deal, but not a near-term event with timing? They announced it, but the closing? Not specified. They mention "we've successfully integrated the Kinh Do snacks business" - past. They mention "we've expanded capacity and flexibility, with the opening of a new U.S.-based manufacturing facility in Indiana." That's past. They mention "This increased capacity enabled our recent expansion into the UK and Australia." Past. So the forward-looking discussion is mostly about market conditions, cost management, and targets.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| BEAT | BioTelemetry's | Q4 2022 | 2023-03-17 | D |
| ARWR | Arrowhead Pharmaceuticals, Inc. | Q4 2022 | 2022-11-28 | D |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| ALKS | Alkermes plc | Q3 2018 | 2018-10-23 | C |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| DUK | Duke Energy Corporation | Q2 2016 | 2016-08-04 | B |
PCRX · Q4 2017 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management frames the near-term outlook (2018) as a concrete calendar of its own named, time-anchored events—nerve-block label expansion, C-section study readout, additional Phase 4 study launches, CMS reimbursement decisions, and new partnerships—treating the execution of this sequence as the primary driver of 2018 growth and strategic progress. These are presented as scheduled company actions rather than general market trends, with explicit timing (e.g., mid-year FDA meetings, second-half manufacturing ramp, AAOS programs) and positioned as the central story of where the company is heading.
AU · Q2 2018 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management structures the forward outlook around a clear sequence of its own named, time-anchored events—Kibali underground ramp-up and Azambi hydropower station (Q3), Siguiri CIL circuit and power plants (Q4), Obuasi redevelopment milestones (first gold end-2019), Mponeng 6-month backfill plant start (H2), South Africa Section 189 process and wage negotiations (Q3), plus production upticks at multiple sites—presenting these as the primary drivers of the next stage rather than generic market or cost themes.
HROW · Q4 2021 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES The transcript shows management organizing the near-term outlook around a clear sequence of its own named, time-anchored events: AMP-100 PDUFA on October 16 (with launch a few months later), Surface Opthalmics data readout in a few months, Melt Pharmaceuticals top-line data soon after, and internal product 18-month launches, plus MAQ-100 FDA meeting mid-year and relaunch preparations for IOPIDINE/MAXITROL/MOXEZA.